Clinical efficacy of etoposide soft capsules oral monotherapy in second-line treatment of elderly patients with recurrent small cell lung cancer
10.3969/j.issn.1005-1678.2016.11.010
- VernacularTitle:足叶乙苷胶囊单药口服二线治疗老年复发小细胞肺癌患者的临床疗效
- Author:
Junjian WANG
;
Ni ZENG
;
Shaoxiang HUANG
- Keywords:
etoposide capsules;
elderly patients of recurrent small cell lung cancer;
second-line treatment
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(11):41-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of etoposide capsule (VP16) in the treatment of recurrent small cell lung cancer. Methods Retrospective analysis 39 patients,aged≥65, with relapsed small cell lung cancer, who were at least three months after the end of the first-line treatment since January 2012 to January 2014 in Tianjin fifth central hospital.Etoposide was administered by daily oral at 100 mg/day for seven consecutive days and withdraw for 14 days,21 days as a therapeutic cycle,repeat treatment until disease progression or intolerable side effects occur, analyze the progression-free survival and overall survival.Observe the clinical benefit rate,the overall response rate and safety.Results The clinical benefit rate (DCR) and overall response rate (ORR) after the treatment were 61.5% and 30.77%.The progression-free survival (PFS) was 2.8 months, and the overall survival (OS) was 7.3 months.Neutropenia is the most common toxicities, and grade Ⅲ or Ⅳ occurred in 7.7% of the patients.No grade Ⅲ or Ⅳ thrombocytopenia, or grade Ⅲ or Ⅳ non-hematologic toxicity was occured.Conclusion Etoposide oral capsules monotherapy may be considered as one of the safe and effective choice of the second-line treatment of elderly patients with relapsed small cell lung cancer.
